How will the tentative FDA approval for Apixaban Oral Suspension affect Somerset?
Lupin gains tentative FDA approval for Apixaban manufacturing in Somerset Lupin has received tentative approval from the U.S. FDA for its New Drug Application regarding Apixaban Oral Suspension 1.25mg/mL. This product is an oral liquid formulation of apixaban, the active ingredient in Eliquis®, used for adult patients needing anticoagulation therapy. Upon final approval, the manufacturing of this product will take place at the company's facility in Somerset, New Jersey.
- Effect
- Strong positive
- How direct
- 2 steps, all reported
- When
- Over the long term
- The story
- Still developing
How it reaches Somerset
-
Lupin Limited received tentative approval from the United States Food and Drug Administration for its New Drug Application for Apixaban Oral Suspension 1.25mg/mL. This formulation is an oral liquid version of apixaban, the active ingredient in Eliquis® manufactured by Bristol-Myers Squibb. If final approval is granted, the product will be manufactured at Lupin's facility in Somerset.
The full event1independent outlet -
Lupin received tentative approval from the U.S. FDA for its New Drug Application for Apixaban Oral Suspension 1.25mg/mL. This approval was granted via the 505(b)(2) pathway.
1 report connects these two. Brind only summarizes; follow a link to read the reporting itself.
- equitybulls.com Yesterday
-
agency of the US Department of Health and Human Services
Everything about United States Food and Drug Administration -
The product, Apixaban Oral Suspension 1.25 mg/mL, is an oral liquid formulation of apixaban. The manufacturing of this product is planned to occur at the Lupin facility located in Somerset, New Jersey, upon final approval.
1 report connects these two. Brind only summarizes; follow a link to read the reporting itself.
- equitybulls.com Yesterday
-
community in Franklin Township, New Jersey, United States
Everything about Somerset
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- Lupin received tentative FDA approval for Apixaban Oral Suspension 1.25mg/mLequitybulls.com
- The approval was sought via the 505(b)(2) pathwayequitybulls.com
- The product is an oral liquid formulation of apixabanequitybulls.com
- Manufacturing will take place at Lupin's Somerset, New Jersey facility upon final approvalequitybulls.com
Why it matters
For Somerset, the tentative approval marks a significant operational development, confirming the location of a major pharmaceutical manufacturing operation. This operation is based on the company's U.S.-based manufacturing expertise and is intended to support high-quality standards and supply reliability.
This development is part of Lupin's strategy to expand its portfolio by developing differentiated medicines. The successful completion of the final approval process will allow the company to move forward with the manufacturing operations in the community.
What we don't know yet
- What are the timelines for the final FDA approval of the Apixaban Oral Suspension?
- What specific operational requirements will the manufacturing process place on the Somerset facility?
What would change this answer
Reporting
- equitybulls.comYesterday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. It explains possible effects; it is not investment advice.